Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00090714
Status:
UNKNOWN
Last Update Posted:
2006-04-20
First Post:
2004-09-02
Brief Title:
To Find the Best Dose of pVGI1VEGF2 to Benefit Angina Patients When Given With an Experimental Injection Catheter
Sponsor:
Corautus Genetics
Organization:
Corautus Genetics
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2006-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the optimum effective dose of recombinant plasmid DNA pVGI1VEGF2 gene therapy administered using an experimental cardiac direct injection catheter Stiletto system needed to benefit patients with severe Angina Pectoris
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NIH RAC 0301-567 | None | None | None |